Follow The Filings

LAB Standard BioTools

Standard BioTools earnings company data as of 8:59 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by LAB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LAB insider trades
  • $14.4M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $503K 350,000 shares at $1.44 +0.5% to stake
    Traded Dec 2–4 Filed Dec 4, 2025
  2. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $10.1M 7,700,000 shares at $1.31 +12% to stake
    Traded Nov 24–25 Filed Nov 26, 2025
  3. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.4M 1,075,000 shares at $1.28 +1.7% to stake
    Traded Nov 18–20 Filed Nov 20, 2025
  4. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.1M 925,000 shares at $1.22 +1.5% to stake
    Traded Nov 13–17 Filed Nov 17, 2025
  5. Casdin Partners Master Fund, L.P. Director, +7 joint filers
    Buy
    $1.4M 1,175,000 shares at $1.17 +1.9% to stake
    Traded Nov 7–12 Filed Nov 12, 2025

Also filed in the last 12 months, not counted as buying or selling: 16 share withholdings for taxes, 13 stock grants, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3
8-K 7.01,9.01
8-K 1.01,1.02,7.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G/A —
8-K/A 9.01
8-K 1.01,7.01,9.01
8-K 3.01
8-K 5.02,5.07,9.01
SCHEDULE 13D —
SCHEDULE 13D/A —
8-K 1.01,3.02,5.01,5.02,7.01,9.01
8-K 8.01
8-K 5.02
8-K 5.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,7.01,9.01
DEF 14A
DEFA14A
8-K 3.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.